Feature

Immunotherapy moves into the breast cancer landscape


 

At this year’s San Antonio Breast Cancer Symposium, investigators presented some encouraging findings for difficult-to-treat patient populations, but issues such as therapy side effects and fertility concerns in younger patients also highlighted the importance of looking closely at the risk-benefit relationship in delivering quality, personalized care to patients with breast cancer.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

BOLERO-1: Everolimus shows strong signal in HER2+ advanced breast cancer
MDedge Hematology and Oncology
Concomitant depression in breast cancer survivors doubles health care costs
MDedge Hematology and Oncology
Accelerated partial breast irradiation effective
MDedge Hematology and Oncology
International study characterizes male breast cancer
MDedge Hematology and Oncology
Adjuvant paclitaxel plus trastuzumab benefits patients with early breast cancer
MDedge Hematology and Oncology
Breast cancer mortality down, but racial differences persist
MDedge Hematology and Oncology
Aromatase inhibitors linked to dental problems
MDedge Hematology and Oncology
Adjuvant taxane benefit for breast cancer varies by subtype
MDedge Hematology and Oncology
Big savings achievable with evidence-based radiotherapy for breast Ca
MDedge Hematology and Oncology
Radiation exposure from diagnostic procedures in patients with newly diagnosed breast cancer
MDedge Hematology and Oncology